Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEVETEN vs EDARBI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective angiotensin II receptor type 1 (AT1) antagonist, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Hypertension,Treatment of hypertension (alone or in combination with other antihypertensive agents)
Treatment of hypertension,Off-label: Diabetic nephropathy, heart failure
400-800 mg orally once daily; can be divided twice daily if needed for adequate blood pressure control.
EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.
Terminal elimination half-life is approximately 7-8 hours in patients with normal renal function, supporting once-daily dosing.
Approximately 20-22 hours in normal subjects; allows once-daily dosing. Half-life increases in moderate to severe hepatic impairment.
Primarily metabolized by glucuronidation (UGT1A3, UGT2B7); minimal CYP450 metabolism.
Primarily metabolized by CYP2C9 and CYP3A4; undergoes dehydrogenation and decarboxylation.
Renal (approximately 60% as unchanged drug) and biliary/fecal (approximately 40%).
Approximately 60% of dose is excreted in feces (primarily as unchanged drug) and 33% in urine (as metabolites, predominantly glucuronide conjugates).
Approximately 99% bound to plasma proteins, primarily albumin.
High (>99% bound to serum proteins, mainly albumin).
Approximately 0.3 L/kg, indicating distribution mainly in extracellular fluid.
Approximately 0.9 L/kg (total Vdss of about 86 L), indicating extensive distribution into tissues.
Oral: approximately 15-20% due to extensive first-pass metabolism; absorption is not significantly affected by food.
Absolute bioavailability is about 15% due to extensive first-pass metabolism (CYP2C9, UGT1A3).
Cr Cl 30-59 m L/min: no adjustment; Cr Cl <30 m L/min: 200-400 mg once daily; hemodialysis: not studied, use with caution.
No dose adjustment is required for patients with mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). For patients with severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease (ESRD), caution is advised; no specific dosing recommendations are available due to limited data. Avoid use in patients undergoing dialysis.
No adjustment required for mild to moderate impairment; not studied in severe impairment (Child-Pugh C).
No dose adjustment is needed for mild hepatic impairment (Child-Pugh class A). For moderate hepatic impairment (Child-Pugh class B), the recommended starting dose is 40 mg once daily; maximum dose is 40 mg once daily. EDARBI should not be used in patients with severe hepatic impairment (Child-Pugh class C).
Safety and efficacy not established in pediatric patients <18 years.
Safety and efficacy in pediatric patients (<18 years) have not been established. Therefore, no dosing recommendation is provided.
No specific adjustment needed, but start at lower end of dosing range (400 mg once daily) due to potential renal impairment and increased sensitivity.
No dose adjustment is required for elderly patients (≥65 years). However, as with all patients, initiate at 40 mg once daily; consider cautious titration due to potential greater sensitivity and increased risk of hypotension.
None
No FDA boxed warnings.
Avoid use in pregnancy (fetal toxicity/neonatal morbidity/mortality),Hypotension in volume-depleted patients (e.g., diuretic therapy, dialysis),Hyperkalemia in patients with renal impairment or potassium-sparing diuretics/supplements,Acute renal failure in patients with bilateral renal artery stenosis or solitary kidney,Monitor renal function and serum potassium periodically
Fetal toxicity: Avoid in pregnancy; discontinue if pregnancy occurs,Hypotension in volume-depleted patients,Renal function impairment: Monitor serum creatinine and potassium,Hyperkalemia: Risk in patients with renal impairment or on potassium-sparing diuretics,Avoid use in patients with bilateral renal artery stenosis
Concomitant use with aliskiren in patients with diabetes mellitus (type 2) or moderate to severe renal impairment (e GFR <60 m L/min/1.73 m²),Hypersensitivity to eprosartan or any component,Pregnancy (especially second and third trimesters)
Concomitant use with aliskiren in patients with diabetes,Hypersensitivity to edarbi or any component,Pregnancy
No specific food interactions. Avoid excessive potassium intake (e.g., potassium-rich foods like bananas, oranges, tomatoes, spinach) as TEVETEN may increase serum potassium. No restrictions with alcohol, but limit intake as it may lower blood pressure and increase side effects. Grapefruit juice has no known interaction.
No significant food interactions. May be taken with or without food. Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, tomatoes) and salt substitutes containing potassium, especially in patients with renal impairment or those on concomitant RAAS inhibitors or potassium-sparing diuretics.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure is associated with a low risk of congenital anomalies, but second- and third-trimester exposure is associated with oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal hypotension, anuria, and renal failure. TEVETEN (eprosartan mesylate) is an angiotensin II receptor blocker, and its use is contraindicated in pregnancy, especially during the second and third trimesters.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure: Potential for fetal renal damage, oligohydramnios, and skull ossification defects. Second and third trimester exposure: Increased risk for oligohydramnios, fetal renal dysfunction, skull hypoplasia, hypotension, and anuria. Use is contraindicated in pregnancy, especially in second and third trimesters.
Eprosartan is excreted in rat milk at concentrations approximately 2.4 times higher than maternal plasma. No data exist on its excretion in human breast milk. Due to the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. The M/P ratio in humans is unknown.
No data on azilsartan medoxomil (EDARBI) excretion in human milk; effects on the breastfed infant and milk production are unknown. Due to the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio unknown.
TEVETEN is contraindicated in pregnancy, and no dose adjustments are recommended because the drug should not be used. If pregnancy is detected, discontinue the drug as soon as possible. Pharmacokinetic changes in pregnancy, such as increased plasma volume, may alter the drug's effect, but use is not advised.
EDARBI is not recommended during pregnancy; if pregnancy is detected, discontinue as soon as possible. No specific dose adjustments have been established for use in pregnancy; pharmacokinetic changes in pregnancy may alter drug exposure, but no data are available to guide dosing.
TEVETEN (eprosartan mesylate) is an angiotensin II receptor blocker (ARB) with a high affinity for the AT1 receptor. It has a dose-dependent antihypertensive effect. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. Monitor renal function and serum potassium in patients with renal impairment, diabetes, or those on potassium-sparing diuretics. May cause angioedema, though rare. Use with caution in patients with unilateral or bilateral renal artery stenosis due to risk of acute renal failure.
Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) with high receptor affinity and a long half-life (~11 hours), allowing once-daily dosing. It is a prodrug that is rapidly hydrolyzed to the active moiety azilsartan. Onset of action within 2 weeks; maximum effect may take 4-6 weeks. Monitor renal function and serum potassium, especially in patients with renal impairment, diabetes, or those taking NSAIDs or potassium-sparing diuretics. Avoid use in pregnancy (category D). Dose adjustment recommended for patients with hepatic impairment (Child-Pugh class B).
Take TEVETEN exactly as prescribed, usually once daily, with or without food.,Do not stop taking this medication without consulting your doctor, as it may worsen your condition.,Avoid becoming pregnant while on TEVETEN; use effective contraception and inform your doctor immediately if you think you are pregnant.,Report any signs of angioedema (swelling of face, lips, throat, difficulty breathing) or fainting to your doctor immediately.,Inform all healthcare providers that you are taking TEVETEN, especially before surgery or any procedure requiring anesthesia.,Stay hydrated, but do not use potassium supplements or salt substitutes containing potassium without medical advice.,Monitor your blood pressure regularly as directed and keep a log to share with your doctor.
Take exactly as prescribed, usually once daily, with or without food.,Do not take if pregnant or planning to become pregnant; use effective contraception.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms such as dizziness, fainting, rapid heartbeat, or signs of kidney problems (e.g., swelling, decreased urination).,If you miss a dose, take it as soon as you remember, but skip if it is almost time for the next dose. Do not double the dose.,Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEVETEN vs EDARBI, answered by our medical review team.
TEVETEN is a Angiotensin II Receptor Blocker that works by Selective angiotensin II receptor type 1 (AT1) antagonist, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.. EDARBI is a Angiotensin II Receptor Blocker that works by Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEVETEN and EDARBI depend on the specific clinical indication. These are both Angiotensin II Receptor Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEVETEN is: 400-800 mg orally once daily; can be divided twice daily if needed for adequate blood pressure control.. The standard adult dose of EDARBI is: EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEVETEN and EDARBI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEVETEN is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure is associated with a l. EDARBI is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure: Potential for fetal r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.